© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 02, 2022
Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.
November 25, 2022
Key opinion leaders provide a comprehensive review of agents under investigation, alone or in combination, in patients with myelofibrosis.
Focusing on real-world management of myelofibrosis, experts share insight on how they would select and sequence therapies within the current paradigm.
November 18, 2022
A review of the treatment armamentarium for patients with myelofibrosis in the context of clinical trial data supporting use of these agents.
Shifting their attention to myelofibrosis, Rami S. Komrokji, MD, and Pankit Vachhani, MD, define differences between various subsets of disease.
November 11, 2022
Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.